Amin Sapna M, Haugh Alexandra M, Lee Christina Y, Zhang Bin, Bubley Jeffrey A, Merkel Emily A, Verzì Anna Elisa, Gerami Pedram
*Department of Dermatology, Feinberg School of Medicine †The Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL.
Am J Surg Pathol. 2017 Apr;41(4):491-498. doi: 10.1097/PAS.0000000000000761.
Recent studies have identified translocations involving the kinase domains of ALK, NTRK1, BRAF, RET, and ROS in spitzoid neoplasms. Subsequent studies have also characterized morphologic features corresponding to ALK and NTRK1 translocations. In this study, we sought to further compare morphologic features across a range of 49 genetically defined spitzoid neoplasms with ALK, NTRK1, BRAF, or RET fusions to determine discriminating features. We also compared them with a group of 22 spitzoid neoplasms, which were confirmed to be negative for fusions in ALK, NTRK1, BRAF, and RET. Features with the highest discriminatory value included diameter of the lesion, dermal architecture, and certain cytomorphologic features. Specifically, cases with a large diameter (≥9 mm) and wedge-shaped, plexiform dermal architecture of nests of large, spindle-shaped cells were most likely to have an ALK fusion. NTRK1-fused cases were most likely of the fusions to have Kamino bodies and were typically arranged in smaller nests with smaller predominantly spindle-shaped cells, occasionally forming rosettes. BRAF fusion cases were the only fusion subtype to have a predominance of epithelioid cells, were less organized in nests, and commonly had a sheet-like growth pattern or dysplastic Spitz architecture. BRAF fusion cases were most likely to have high-grade nuclear atypia, to be diagnosed as spitzoid melanoma, to have a positive result by melanoma fluorescence in situ hybridization assay, and to develop copy number gains in the kinase domain of the fusion protein. On the basis of experience from this cohort, BRAF-fused cases appear most likely to progress to melanoma.
最近的研究已在Spitzoid肿瘤中发现涉及ALK、NTRK1、BRAF、RET和ROS激酶结构域的易位。随后的研究还描述了与ALK和NTRK1易位相对应的形态学特征。在本研究中,我们试图进一步比较49例基因定义的具有ALK、NTRK1、BRAF或RET融合的Spitzoid肿瘤的形态学特征,以确定鉴别特征。我们还将它们与一组22例Spitzoid肿瘤进行了比较,这些肿瘤经证实ALK、NTRK1、BRAF和RET融合均为阴性。具有最高鉴别价值的特征包括病变直径、真皮结构和某些细胞形态学特征。具体而言,直径较大(≥9mm)且具有大的梭形细胞巢的楔形、丛状真皮结构的病例最有可能存在ALK融合。NTRK1融合病例最有可能有卡米诺小体,通常排列成较小的巢,主要由较小的梭形细胞组成,偶尔形成玫瑰花结。BRAF融合病例是唯一以上皮样细胞为主的融合亚型,巢状结构较差,通常具有片状生长模式或发育异常的Spitz结构。BRAF融合病例最有可能具有高级别核异型性,被诊断为Spitzoid黑色素瘤,黑色素瘤荧光原位杂交检测呈阳性,并且融合蛋白的激酶结构域出现拷贝数增加。根据该队列的经验,BRAF融合病例似乎最有可能进展为黑色素瘤。